Last reviewed · How we verify
Oxygen 99.7 %
Oxygen 99.7 % is a Medical gas Small molecule drug developed by University of South Florida. It is currently in Phase 3 development for Hypoxemia and respiratory insufficiency (indication under investigation in Phase 3).
Medical-grade oxygen at 99.7% purity provides supplemental oxygen to tissues to treat hypoxemia and improve oxygenation in patients with respiratory insufficiency.
Medical-grade oxygen at 99.7% purity provides supplemental oxygen to tissues to treat hypoxemia and improve oxygenation in patients with respiratory insufficiency. Used for Hypoxemia and respiratory insufficiency (indication under investigation in Phase 3).
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Oxygen 99.7 % |
|---|---|
| Sponsor | University of South Florida |
| Drug class | Medical gas |
| Modality | Small molecule |
| Therapeutic area | Respiratory / Critical Care |
| Phase | Phase 3 |
Mechanism of action
Oxygen is a fundamental element required for aerobic cellular respiration. When administered at high purity, it increases the partial pressure of oxygen in the blood, improving oxygen delivery to tissues and organs. This is particularly beneficial in conditions where natural oxygen uptake is impaired due to lung disease, cardiac dysfunction, or other pathological states.
Approved indications
- Hypoxemia and respiratory insufficiency (indication under investigation in Phase 3)
Common side effects
- Oxygen toxicity (with prolonged high-concentration exposure)
- Absorption atelectasis
- Drying of mucous membranes
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Oxygen 99.7 % CI brief — competitive landscape report
- Oxygen 99.7 % updates RSS · CI watch RSS
- University of South Florida portfolio CI
Frequently asked questions about Oxygen 99.7 %
What is Oxygen 99.7 %?
How does Oxygen 99.7 % work?
What is Oxygen 99.7 % used for?
Who makes Oxygen 99.7 %?
What drug class is Oxygen 99.7 % in?
What development phase is Oxygen 99.7 % in?
What are the side effects of Oxygen 99.7 %?
Related
- Drug class: All Medical gas drugs
- Manufacturer: University of South Florida — full pipeline
- Therapeutic area: All drugs in Respiratory / Critical Care
- Indication: Drugs for Hypoxemia and respiratory insufficiency (indication under investigation in Phase 3)
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing